ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0932

Compartment-specific NK-cell phenotypes reveal distinct maturation and activation states in inflammatory arthritis
Abstract Number: 0933

Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Abstract Number: 0934

The Use Of Preclinical Models To Understand Drivers Of Lupus Pathogenesis
Abstract Number: 0935

Oral Antibiotic Treatment Reduces Anxiety in a Murine Model of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Abstract Number: 0936

Ultrasound-Mediated Blood–Brain Barrier Permeabilization Enables Targeted Drug Delivery in a Murine Model of Neuropsychiatric SLE
Abstract Number: 0937

MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
Abstract Number: 0938

Short Term Antibiotic Treatment Improves the Neurobehavioral Phenotype of MRL/lpr Mice
Abstract Number: 0939

Exploring the Mechanism of Action and Related Biomarkers of BTK Inhibitor/Degrader in Systemic Lupus Erythematosus
Abstract Number: 0940

Resident Macrophages Localize Near Fibroblasts and Drive Reprogramming in Lupus Nephritis Through Direct and Soluble Signaling
Abstract Number: 0941

In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Abstract Number: 0942

Sodium-Glucose Co-Transporter 2 Inhibitors Modulate Renal Injury and Autoreactive Plasma Cells in Lupus
Abstract Number: 0943

Type I and Type II IFNs have both independent and overlapping effects on SLE disease severity
Abstract Number: 0944

L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis
Abstract Number: 0945

Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization
Abstract Number: 0946

A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].